Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pelegrí, A.
Right arrow Articles by Rubiés-Prat, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pelegrí, A.
Right arrow Articles by Rubiés-Prat, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 623-626
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis

A. Pelegrí1,4, R. Romero2, M. Sentí3, X. Nogués3, J. Pedro-Botet3 and J. Rubiés-Prat3

1Department of Nephrology, Quinta La Salut l'Alianca Barcelona 2Department of Nephrology, Hospital Germans Trias i Pujol, Badalona 3Department of Medicine, Hospital del Mar, Instituto Municipal de Investigatiòn Médica, Universidad Autónoma de Barcelona Barcelona, Spain

Correspondence and offprint requests to: 4Professor J. Rubies-Prat, Department of Medicine, Hospital del Mar, Paseo Maritimo 25–29, 08003 Barcelona, Spain

The effect of bezafibrate, at doses of 200 mg three times weekly throughout a period of 10 weeks, on lipoprotein (a) and triglyceride-rich lipoproteins including intermediate-density lipoproteins (IDL) has been studied in 12 patients with chronic renal failure receiving haemodialysis. No side-effects were observed, and serum creatine phosphate kinase values remained within normal limits throughout the duration of the study. Serum cholesterol, triglycerides and apoprotein (apo) B significantly decreased after bezafibrate, whereas apo A-I increased significantly. Serum lipoprotein (a) decreased after bezafibrate, although differences reached no statistical significance. The very-low-density lipoproteins (VLDL) cholesterol and the VLDL triglycerides decreased from 0.93 ± 0.45 mmol/1 (Mean ± SD) to 0.54 ± 0.27 mmol/1 (P<0.05) and from 1.50 ± 0.58 mmol/1 to 0.91 ± 0.35 mmol/1 (P<0.01) respectively. The IDL cholesterol and IDL triglycerides decreased from 0.44 ± 0.35 mmol/1 to 0.20 ± 0.18 mmol/1 (P=NS) and from 0.46 ± 0.35 mmol/1 to 0.17 ± 0.12 mmol/1 (P<0.05) respectively. These data, with a substantial improvement of the lipoprotein profile in patients with chronic renal failure on haemodialysis after treatment with bezafibrate, suggest a decrease in the coronary heart disease risk

Keywords: bezafibrate; chronic renal failure; haemodialysis; intermediate-density lipoproteins; lipoprotein (a); triglyceride-rich lipoproteins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.